Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Periodical Presumptive Treatment of Gonorrhoea in Female Sex Workers: Impact on Prevalence of the Disease in Sex Workers and Their Clients
Brief Summary: In the early years of the HIV epidemic in Africa, female sex workers (FSWs) were identified as a high-prevalence, high-incidence, core group among whom the extraordinary prevalence of other sexually transmitted infections (STIs) facilitated transmission of the virus to their clients, who then infected low-risk women not involved in the sex trade. In resource-poor settings, control of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) among FSWs is difficult. The purpose of this study is to determine whether periodical antibiotic treatment (PAT) is effective in controlling these infections among West African FSWs.

The study is designed as a cluster-randomized double-blind placebo-controlled trial conducted in West Africa. The study population consists of "seaters" FSWs who work from their homes in well-defined areas. Clusters will be paired according to their size and demographic characteristics of FSWs and clients. Within each pair, one cluster will be randomly allocated to the intervention and the other to the placebo group.

At enrollment, participants will be interviewed, a pelvic examination performed, cervical swabs obtained for NG and CT polymerase chain reaction (PCR), and current cervicitis or vaginitis managed syndromically. Blood specimens will be obtained for HIV testing. All participants will be given free condoms and counseled on risk reduction.

Monthly follow-up will be conducted within FSW communities, alternating with clinic visits where cervical samples will be collected. Study drugs (azithromycin 1 g and ciprofloxacin 500 mg, and their identical placebos) will be distributed every month according to a predefined schedule: directly-observed intake of azithromycin at months 1, 4 and 7, and ciprofloxacin at months 2, 3, 5, 6, 8 and 9.

Data will be analyzed with SAS. The investigators will assess the time trends in NG and CT prevalence separately in both study groups using χ2-for-trend.


Options:
A: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
B: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Monthly placebo | Arm Label: Treatment arm; Type: EXPERIMENTAL; Interventions: Drug: Monthly antibiotic | Intervention Type: DRUG; Name: Monthly antibiotic; Assigned to Arm(s): Treatment arm | Intervention Type: DRUG; Name: Monthly placebo; Assigned to Arm(s): Sugar pill
C: Intervention Type: BEHAVIORAL; Name: Intervention with Microfinance for AIDS and Gender Equity; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Atazanavir, Drug: Didanosine, Drug: Efavirenz, Drug: Emtricitabine/Tenofovir disoproxil fumarate, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine, Drug: Tenofovir disoproxil fumarate, Drug: Zidovudine/Lamivudine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Atazanavir, Drug: Didanosine, Drug: Efavirenz, Drug: Emtricitabine/Tenofovir disoproxil fumarate, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine, Drug: Tenofovir disoproxil fumarate, Drug: Zidovudine/Lamivudine | Intervention Type: DRUG; Name: Atazanavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Emtricitabine/Tenofovir disoproxil fumarate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Tenofovir disoproxil fumarate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine/Lamivudine; Assigned to Arm(s): 1, 2

Answer: B